CL2017001024A1 - Formulación de buprenorfina inyectable - Google Patents

Formulación de buprenorfina inyectable

Info

Publication number
CL2017001024A1
CL2017001024A1 CL2017001024A CL2017001024A CL2017001024A1 CL 2017001024 A1 CL2017001024 A1 CL 2017001024A1 CL 2017001024 A CL2017001024 A CL 2017001024A CL 2017001024 A CL2017001024 A CL 2017001024A CL 2017001024 A1 CL2017001024 A1 CL 2017001024A1
Authority
CL
Chile
Prior art keywords
buprenorfine
provides
liquid composition
administration
formulation
Prior art date
Application number
CL2017001024A
Other languages
English (en)
Inventor
Fredrik Tiberg
Markus Johnsson
Ian Harwigsson
Original Assignee
Camurus Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52103459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001024(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Camurus Ab filed Critical Camurus Ab
Publication of CL2017001024A1 publication Critical patent/CL2017001024A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA UNA FORMULACIÓN LIQUIDA INYECTABLE QUE COMPRENDE: A) UNA MATRIZ DE LIBERACIÓN CONTROLADA DE LÍPIDOS QUE COMPRENDE AL MENOS 50% DE LÍPIDOS TRIACILO; AL MENOS UN OXIGENO QUE CONTIENE DISOLVENTE ORGÁNICO; POR LO MENOS 16% EN PESO DE AL MENOS UN AGENTE ACTIVO SELECCIONADO DE BUPRENORFINA Y SALES DE LA MISMA, CALCULADO COMO BASE LIBRE DE BUPRENORFINA. LA INVENCIÓN PROPORCIONA ADEMÁS UNA COMPOSICIÓN DE LIBERACIÓN CONTROLADA, FORMADA POR  LA ADMINISTRACIÓN DE DICHA COMPOSICIÓN LIQUIDA INYECTABLE A UN SUJETO PREFERIBLEMENTE HUMANO. LA INVENCIÓN PROPORCIONA TAMBIÉN UN MÉTODO DE ADMINISTRACIÓN DE BUPRENORFINA A UN SUJETO QUE COMPRENDE INYECTAR DICHA COMPOSICIÓN LIQUIDA Y UN MÉTODO PARA EL TRATAMIENTO DEL DOLOR, PARA TERAPIA DE MANTENIMIENTO DE OPIOIDES O PARA EL TRATAMIENTO DE LA DEPENDENCIA DE OPIOIDES POR MEDIO DE DESINTOXICACIÓN Y/O MANTENIMIENTO O PARA EL TRATAMIENTO O PROFILAXIS DE LOS SÍNTOMAS DE ABSTINENCIA DE OPIOIDES Y/O ABSTINENCIA DE LA COCAÍNA INYECTANDO DICHA COMPOSICIÓN LÍQUIDA.</p>
CL2017001024A 2014-10-27 2017-04-25 Formulación de buprenorfina inyectable CL2017001024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1419091.2A GB201419091D0 (en) 2014-10-27 2014-10-27 Formulations

Publications (1)

Publication Number Publication Date
CL2017001024A1 true CL2017001024A1 (es) 2017-11-10

Family

ID=52103459

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001024A CL2017001024A1 (es) 2014-10-27 2017-04-25 Formulación de buprenorfina inyectable

Country Status (17)

Country Link
US (3) US20180015031A1 (es)
EP (1) EP3212168A1 (es)
JP (1) JP6768648B2 (es)
KR (2) KR102541281B1 (es)
CN (1) CN107205920B (es)
AU (1) AU2015340661B2 (es)
BR (1) BR112017008721A2 (es)
CA (1) CA2964045C (es)
CL (1) CL2017001024A1 (es)
EA (1) EA033935B1 (es)
GB (1) GB201419091D0 (es)
IL (1) IL251413B2 (es)
MX (1) MX389333B (es)
MY (1) MY183540A (es)
SG (1) SG11201703158WA (es)
TW (1) TW201625250A (es)
WO (1) WO2016066655A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2837803T3 (es) 2012-07-26 2021-07-01 Camurus Ab Formulaciones de opioides
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations
US20160128997A1 (en) 2014-11-07 2016-05-12 Indivior Uk Limited Sustained-release buprenorphine formulations
PL3512518T3 (pl) * 2016-09-13 2023-03-27 Alar Pharmaceuticals Inc. Preparaty buprenorfiny o przedłużonym uwalnianiu
JP7527785B2 (ja) 2016-09-15 2024-08-05 カムルス エービー プロスタサイクリン類似体製剤
MX383392B (es) 2016-09-27 2025-03-13 Camurus Ab Mezclas y formulaciones que comprenden una sal de alquil amonio de ácido etilendiaminotetraacético (edta).
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2023020608A1 (zh) * 2021-08-20 2023-02-23 苏州恩华生物医药科技有限公司 一种包含塞纳布啡的药物组合物
WO2025229403A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof
WO2025229402A1 (en) 2024-05-02 2025-11-06 Camurus Ab Lipid compositions and methods of use thereof
WO2026125238A1 (en) 2024-12-10 2026-06-18 Camurus Ab Compositions and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
ATE382050T1 (de) * 2002-11-25 2008-01-15 Chi Mei Foundation Medical Ct Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel
PL1768650T3 (pl) 2004-06-04 2009-01-30 Camurus Ab Ciekłe formulacje depot
JP2011528379A (ja) * 2008-07-17 2011-11-17 メリアル リミテッド ポリオルトエステルの安定性を増強する方法及びそれらの処方物
GB2469792A (en) 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
GB2481018B (en) * 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
AU2013294915C1 (en) * 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
CN103142458B (zh) 2013-01-22 2015-09-09 莱普德制药有限公司 无成瘾性镇痛缓释递药系统的组方与制备方法
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations

Also Published As

Publication number Publication date
NZ730521A (en) 2023-11-24
IL251413B1 (en) 2023-01-01
IL251413A0 (en) 2017-05-29
EA033935B1 (ru) 2019-12-11
KR20170072237A (ko) 2017-06-26
AU2015340661B2 (en) 2018-04-26
IL251413B2 (en) 2023-05-01
JP6768648B2 (ja) 2020-10-14
BR112017008721A2 (pt) 2018-01-30
GB201419091D0 (en) 2014-12-10
CA2964045A1 (en) 2016-05-06
JP2017532354A (ja) 2017-11-02
WO2016066655A1 (en) 2016-05-06
MX389333B (es) 2025-03-20
KR102541281B1 (ko) 2023-06-13
CN107205920B (zh) 2021-05-25
CN107205920A (zh) 2017-09-26
MY183540A (en) 2021-02-25
US20250041205A1 (en) 2025-02-06
US12396944B2 (en) 2025-08-26
US20180015031A1 (en) 2018-01-18
CA2964045C (en) 2023-03-07
US12029813B2 (en) 2024-07-09
US20210308041A1 (en) 2021-10-07
TW201625250A (zh) 2016-07-16
SG11201703158WA (en) 2017-05-30
KR20230039767A (ko) 2023-03-21
EA201790721A1 (ru) 2017-09-29
AU2015340661A1 (en) 2017-04-20
EP3212168A1 (en) 2017-09-06
MX2017005461A (es) 2018-01-17

Similar Documents

Publication Publication Date Title
MX2017005461A (es) Formulacion de buprenorfina inyectable.
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
CL2019001369A1 (es) Composición farmacéutica para prevenir o tratar el cáncer de mama, incluido el polimorfo cristalino del hexoxido tetraarsenico y el método para producirlo.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
CO2018002060A2 (es) Compuestos farmacéuticos
MX2021014049A (es) Compuestos espiro triciclicos.
MX2017000408A (es) Compuestos antiproliferativos y métodos de uso de los mismos.
MX2019009695A (es) Inhibidores espirociclicos de catepsina c.
BR112017006113A8 (pt) usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits.
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
MX2015000990A (es) Analogos del glucagon.
MX2016012103A (es) Agonistas del receptor muscarinico.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
MX2017006113A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
CU20200008A7 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen
CY1124016T1 (el) Φαρμακοτεχνικες μορφες οπιοειδων
MX381776B (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
CL2017001539A1 (es) Compuestos indenil, composiciones farmacéuticas y sus usos médicos de los mismos
NI201600091A (es) UREAS ASIMÉTRICAS p-SUSTITUIDAS Y USOS MÉDICOS DE LAS MISMAS
AR100444A1 (es) Uso de palmitoiletanolamida en combinación de opioides
MX2017003469A (es) Inhibidores macrociclicos de cinasa rip2.
MX349767B (es) Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular.